">
Tuesday, 17 March 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 17 March 2026
News

$130K fine for Aussie Code breach

 Posted 5 December 2025 PM

Amgen has been slugged with a $130,000 fine by the Medicines Australia Code of Conduct Committee following a complaint by Novartis about material comparing the companies cholesterol-lowering drugs.

In addition, Amgen lost another $20,000 after failing to win on appeal. The Code breaches related to misleading material produced by Amgen in relation to Repatha which included comparisons with inclisiran which is the active in Novartis' Leqvio. Both drugs are injectable treatments for high cholesterol.

To see the whole article, please login

Popular

Minister wins blockbuster price cut case
Last ditch effort to keep exclusivity
CEO pay packet rockets by 75%
GSK tops Kosi fundraising peak
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home